DaVita Inc. (NYSE:DVA) Stock Has Average Price Target of $233.43

Key Points

• Analysts hold a moderately bullish view of DaVita: four of seven analysts rate the stock a buy and three recommend holding it, with an average 12-month price target of $233.43 versus the recent price of $182.05.
• DaVita’s latest quarterly results exceeded expectations, with EPS of $4.02 versus the $3.88 consensus and revenue of $3.55 billion versus $3.50 billion; revenue increased 5.2% year over year.
• Institutional investors and hedge funds own approximately 90.12% of DaVita’s shares, while the company projects fiscal 2026 EPS of $14.10 to $15.20.

Shares of DaVita Inc. (NYSE:DVA - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven ratings firms that are covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $233.43.

DVA has been the subject of several recent analyst reports. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and issued a $265.00 target price on shares of DaVita in a research report on Wednesday, August 5th. Oppenheimer set a $220.00 price objective on DaVita in a report on Friday, August 7th. Truist Financial dropped their target price on shares of DaVita from $250.00 to $215.00 and set a "hold" rating for the company in a research report on Friday, August 7th. Barclays lifted their target price on DaVita from $218.00 to $224.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 5th. Finally, UBS Group boosted their price objective on shares of DaVita from $235.00 to $270.00 and gave the company a "buy" rating in a report on Friday, July 10th.

DaVita Stock Up 0.1%

DVA stock traded up $0.27 during trading on Tuesday, hitting $182.05. 31,048 shares of the company's stock traded hands, compared to its average volume of 893,150. The stock has a fifty day moving average price of $181.31 and a two-hundred day moving average price of $189.98. DaVita has a 52 week low of $101.00 and a 52 week high of $247.49. The stock has a market capitalization of $11.61 billion, a price-to-earnings ratio of 14.88, a price-to-earnings-growth ratio of 0.46 and a beta of 0.80.

DaVita (NYSE:DVA - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, topping the consensus estimate of $3.88 by $0.14. The firm had revenue of $3.55 billion during the quarter, compared to analysts' expectations of $3.50 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. DaVita's quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.95 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities research analysts expect that DaVita will post 14.57 EPS for the current fiscal year.

Hedge Funds Weigh In On DaVita

A number of institutional investors have recently added to or reduced their stakes in DVA. NorthCrest Asset Manangement LLC acquired a new stake in DaVita in the 3rd quarter worth about $209,000. Wedmont Private Capital raised its holdings in DaVita by 13.3% in the 3rd quarter. Wedmont Private Capital now owns 2,082 shares of the company's stock valued at $369,000 after buying an additional 244 shares during the last quarter. Farther Finance Advisors LLC grew its position in shares of DaVita by 62.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,362 shares of the company's stock valued at $413,000 after buying an additional 905 shares during the last quarter. Westwind Capital acquired a new stake in shares of DaVita during the third quarter worth $1,251,000. Finally, CoreCap Advisors LLC grew its stake in DaVita by 161.7% during the third quarter. CoreCap Advisors LLC now owns 157 shares of the company's stock worth $27,000 after purchasing an additional 97 shares during the period. 90.12% of the stock is currently owned by institutional investors and hedge funds.

DaVita Company Profile

DaVita Inc is a healthcare company focused on kidney care and renal disease management. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with end-stage kidney disease, including hemodialysis and peritoneal dialysis, as well as home dialysis support.

The company also operates hospital-based dialysis programs and offers clinical, administrative and care-coordination services intended to support patients across the kidney-care journey.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.